Bladder cancer is the fifth commonest malignancy in the United States with 70 530 new cases and 14 680 deaths in 2010 ([@bib13]). The majority of urothelial cell carcinoma (UCC) is low grade and non-muscle invasive. These are managed by endoscopic resection with intra-vesical chemotherapy, and have an excellent prognosis. Approximately 1/3 of UCC is high-grade and arises from carcinoma *in-situ*. High-grade UCC is an aggressive disease that may be detected before or with muscle invasion. Despite radical therapy the mortality from invasive UCC is a round 50%, reflecting the late stage at diagnosis and a poor response to chemotherapy ([@bib21]). The relapsing natural history of UCC and the frequency of suggestive symptoms mean that many patients undergo diagnostic or repeated surveillance endoscopic inspection of their bladder. Consequently, bladder cancer is one of the most-expensive human malignancies. Estimates suggest the disease costs around \$3.7 billion/per annum in the US and the majority of this cost is spent on diagnosis and surveillance of disease ([@bib19]; [@bib1]).

A robust urinary biomarker to detect UCC would considerably improve the care of patients with and reduce the cost of managing bladder cancer. Urine cytology is the most used non-invasive urinary test for UCC. It has a high specificity but a low sensitivity for UCC and is poor at detecting low-grade tumours ([@bib18]; [@bib2]). Multiple molecular urinary biomarkers have been investigated to date, but none are sufficiently robust to enter clinical practice ([@bib25]). Many biomarkers fail as they are unable to detect both low and high-grade UCC, which are characterised by distinct molecular pathways and share few molecular alterations ([@bib6], [@bib7], [@bib4]). Biomarker panels that assess molecular events characteristic of low- and high-grade UCC improve the accuracy of urinary tests, but are laborious ([@bib23]).

MicroRNAs (miRs) are short non-coding RNA molecules that post-transcriptionally modulate protein expression ([@bib5]). Alterations in miR expression appear important for carcinogenesis ([@bib12]; [@bib24]) and those with differential expression between normal urothelium and UCC have recently been described ([@bib7]; [@bib9]). Their expression varies with disease phenotype and reflects genetic or epigenetic events within the low- and high-grade UCC pathways ([@bib8]). Here, we test the hypothesis that urinary miR expression can detect bladder cancer. Urine contains many nucleases, and assays to examine mRNA expression often fail due to target degradation or require stringent pre-laboratory handling of the urine sample. Short RNA molecules are less prone to degradation than long polyadenylated mRNAs and may be stabilized by secretion within exosomes ([@bib22]). Recently, urinary miR expression has been reported and the upregulation of miRs-126/182/199a found to discriminate patients with UCC from disease-free controls ([@bib11]). This combination identified up to 77% of UCC cases, despite a lack of differential expression for any of these miRs in malignant and normal urothelium ([@bib7]). We hypothesise that analysing the expression of miRs characteristic of high- and low-grade UCC could improve the performance of a miR-based urinary test for the disease.

Materials and methods
=====================

Patients and samples
--------------------

We studied freshly voided urine samples obtained from 121 patients of the Department of Urology, Royal Hallamshire Hospital, UK ([Table 1](#tbl1){ref-type="table"}). These included 68 patients with current UCC (both new and recurrent tumours) and 53 age-matched controls without a history of UCC. Controls included those requiring cystoscopy for symptoms suggestive of UCC (e.g. haematuria), those undergoing treatment of benign urinary conditions and patients without urinary pathology. Most patients with urinary symptoms, uropathology or haematuria underwent cystoscopy (50/53, 94%). Around 100--150 ml of urine was collected from each patient before instrumentation or bladder tumour removal. Tumours were classified using the 1973 WHO criteria by a specialist uropathologist (SLM). Informed consent was obtained from each patient and institutional ethics committee approval gained before commencing the study.

Urine processing and RNA extraction
-----------------------------------

Freshly voided urine was stored at 4 ^o^C for up to 4 h and then centrifuged at 3392 **g** for 10 min. The supernatant was removed and the cell pellet washed twice in PBS before freezing at −80^o^C until use. To determine miR stability in urine, we split 25 samples into three fractions (50 ml for each) and separately extracted RNA in the form of two reference genes (RNU48 and RNU44) and three miRs (15b/135b/1224-3p) from an immediately processed sample, following three cycles of freeze-thawing (−80 ^o^C to room temperature) and following storage at room temperature for 48 h. We also compared miR yield using matched samples collected into an empty container and into one containing 50% volume RNase inhibitor. RNA was extracted from cell pellets using the mirVana kit (Ambion, Austin, TX, USA) according to the manufacturer\'s protocol and measured using a 2100 Bioanalyzer (Agilent, Stockport, UK).

MiR detection
-------------

The expression of 15 miRs was measured using real-time PCR. We selected miRs including (i) those with differential expression in malignant and normal urothelium, (ii) miRs with up- and downregulation in UCC, (iii) miRs representative of all UCC (miR-135b), of high-grade UCC (miR-21) and of low-grade UCC (miRs-100/133b), (iv) miRs subject to epigenetic regulation (miRs-212/328/1224-3p) and (v) those located in an epigenetic hotspot on chromosome 9 (miRs-23b/24-1/27b: a chromosome commonly deleted in UCC) ([@bib8]). We included RNAs with low and high cellular expression to estimate the necessary abundance for analytical reliability. Quantitation was determined relative to snoRNA\'s, of which we evaluated RNU44 and RNU48. Complementary DNA synthesis was performed using 1--350 ng RNA, multiplex hairpin primers (Megaplex RT Primers, Applied Biosystems, Warrington, UK), 100 mℳ deoxynucleotide triphosphates, 25 mℳ magnesium-chloride, 20 U *μ*l^−1^ RNase inhibitor, nuclease-free water, buffer and Multiscribe Reverse Transcriptase (Applied Biosystems). This reaction was subjected to 40 cycles of 16 ^o^C for 2 min, 42 ^o^C for 1 min and 50 ^o^C for 1 min, before heating to 85 ^o^C for 5 min. We used a nested PCR approach to determine cDNA concentration, as our starting RNA concentration was low. Reverse transcribed cDNA (2.5 *μ*l) was added to a commercially mixed buffer, polymerase and dNTPs (Pre-Amp Mastermix, Applied Biosystems), and mixed with nested primers (Megaplex Pre-Amp primers, Applied Biosystems) and nuclease-free water. This reaction was heated to 95 ^o^C for 10 min, 55 ^o^C for 2 min, 72 ^o^C for 2 min followed by 12 cycles of 95 ^o^C for 15 s, 60 ^o^C for 15 s after which it was finally heated to 99.9 ^o^C for 10 min. Real-time PCR was conducted using this nested cDNA product, nuclease-free water, Mastermix (TaqMan Pre-Amp Mastermix, Applied Biosystems) and individual miR primers and probes. This reaction was analysed using an ABI 7900HT real-time PCR system. Amplification plots were checked manually using detection software (SDS Version. 2.2.1, Applied Biosystems) to confirm the Ct value corresponded with the midpoint of logarithmic amplification.

Statistical methods
-------------------

Relative miR concentrations were calculated with respect to reference snoRNAs (ΔCt=Ct miR−Ct reference) and inter-class fold changes computed using the 2^-ΔΔCt^ function ([@bib20]). Comparisons were performed using Chi squared and *T*-tests or ANOVA tests, as appropriate. Concordance with diagnosis was calculated as described by Harrell ([@bib3]). Unsupervised hierarchical clustering was performed using ΔCt values in Cluster 3.0 and visualised in Tree view (Eisen Lab, [www.rana.lbl.gov](http://www.rana.lbl.gov)).

Results
=======

Urinary miR collection, extraction and quantification
-----------------------------------------------------

Before the sample collection we evaluated three aspects of miR handling and quantification. Firstly, we investigated the use of an RNase inhibitor. We found urinary miR yields were no different with or without the use of RNase inhibition (data not shown) and so collected samples into empty universal containers. Secondly, we subjected matching fractions from 25 freshly-frozen and thawed urine samples to (i) immediate processing, (ii) storage at room temperature for 48 h and (iii) three cycles of freeze-thawing. No statistical difference in yield was shown for both the reference genes RNU48 and RNU44, and miRs-15b/-135b/-1224-3p between urine samples that were immediately processed and those that were stored in room temperature for 48 h before extraction ([Figure 1A](#fig1){ref-type="fig"}). However, freeze-thawing did reduce yields for several RNAs when compared with immediate processing. We used immediate processing for the samples in this report. Thirdly, we compared two snoRNAs to identify the best reference molecule for relative miR quantification. RNU48 was detected in all cases, with a higher and less variable expression (*n*=121 (100%), Ct average±s.d.: 20.8±4.3) than RNU44 (*n*=114 (94%), Ct 28.7±6.45). We chose RNU48 as the reference RNA.

Urinary miR expression in patients with bladder cancer and controls
-------------------------------------------------------------------

Expression of miR varied by 30-million-fold from the lowest (miR-133b) to highest (miR-203) (ΔΔCt=−24.8, [Figure 1B](#fig1){ref-type="fig"}). MicroRNAs with low concentration were less frequently detected than those with high expression (10% *vs* 93%, respectively, Chi sq *P*\<0.001). Reliable detection (e.g. in \>80% of samples) was seen in miRs with a 9000 fold change in expression (miR-203 to miR-100, ΔΔCt=−13.1, fold change=8964). The miRs were detected more frequently in urinary samples from benign than UCC cases ([Table 2](#tbl2){ref-type="table"}). This difference reached significance for nine miRs (miRs-15a/15b/24-1/27-b/100/203/212/328/1224 (Chi Sq *P*\<0.03)). Quantification revealed differences in expression for 10 miRs between benign and malignant cases (ANOVA *P* \<0.05). Patients with UCC had lower expression of miRs-15a/15b/24-1/27b/100/203/212/328/1224-3p and higher expression of miR-135b, when compared with controls.

Non-invasive diagnosis of bladder cancer
----------------------------------------

We calculated the diagnostic performance for UCC of the differentially expressed miRs, using expression dichotomized around the mean ΔCt ([Figure 2](#fig2){ref-type="fig"}). The accuracy of individual miRs varied from 0.61 to 0.80 for UCC (Concordance indices, [Table 2](#tbl2){ref-type="table"}). The sensitivity and specificity for UCC ranged from 51.7% (miR-15a) to 75.9% (miR-1224-3p) and 58.5% (miR-24-1) to 86.8% (miRs-212/328), respectively. MiR-1224-3p had the best individual performance with specificity, positive and negative predictive values of 83%, 83% and 75%, respectively. The combination of miRs improved their diagnostic performance. The best concordance for UCC was achieved using either a combination of eight (C-index 0.86, miRs-15a/15b/27b/100/135b/203/212/1224-3p) or three miRs (C-index 0.86, miRs-15b/135b/1224-3p, [Figure 3](#fig3){ref-type="fig"}). The three miR combination appeared most sensitive for UCC (94.1%), but had a low specificity (51%). Clustering using these selected panels separated the samples into two large cohorts representing mostly benign or UCC cases, and a small intermediate group (*n*=23, 19% [Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

Here, we have shown that urinary miRs appear promising biomarkers for the detection of bladder cancer. When compared with previously analysed candidates, their stability and flexibility in measurement makes them appealing diagnostic targets. By incorporating miRs with known changes in UCC, we found it possible to design a panel with a high sensitivity for the disease. Of note, when implementing a urinary test to stratify the need for cystoscopy, it is sensitivity (to reduce false negative tests) that is more important than specificity.

Firstly, the expression of urinary miRs appears stable *ex vivo* when stored at room temperature. This stability may be due to their small size that makes them less likely to fragment than large RNAs, their lack of polyadenylated tail that nucleases target ([@bib10]), or that they are secreted within exosomes, which protect RNA from degradation ([@bib22]). Exogenously administered free miR undergoes rapid clearance in biological fluids, suggesting the inclusion within an exosome is critical for protection ([@bib16]). This *ex vivo* stability is important in clinical use, where transit to laboratory of biological samples is inconsistent.

Secondly, it is possible to multiplex miR assays into custom combinations to detect specific diseases. With this in mind, we selected 15 miRs whose expression is relatively UCC-specific and were representative of the low- and high-grade tumour pathways ([@bib7], [@bib5]). We included those with functional roles in urothelial carcinogenesis, such as growth promotion through FGFR3 targeting (miR-100) and apoptosis avoidance/cell cycle regulation (miR-21), and those with epigenetic regulation (e.g. miR-1224-3p). We found that low abundance miRs are not reliably detected in urinary cells, even though their expression may be UCC-specific (such as miR-133b). We identified 13 miRs whose urinary presence or expression was abnormal in the UCC patients when compared with controls. Of these, several had alterations that matched primary tumours and was in keeping with their carcinogenic roles (e.g. miR-135b and miR-100). Potentially the most useful was miR-135b, as this was one of only two upregulated species and is one of the most overexpressed miRs UCC tissue ([@bib7]). Similar observations are detailed in colorectal cancer, where miRs-135b/135a are implicated in APC silencing ([@bib17]). In UCC, predicted targets for miR-135b include LATS2 ([@bib7]) and Annexin A7. When combined, we found three miRs with a high sensitivity for UCC (miRs-135b/15b/1224-3p (94.1%)). Implementing this panel in our cohort, would have avoided 31 (26%) cystocopies, but missed four cancers. Of these, two were invasive and two low-grade non-invasive UCC (thus, the risk of missing a significant tumour was 2/63 (3%)).

Our experiments revealed that most urinary miRs are downregulated in the presence of UCC, when compared with controls. This was a surprising outcome as we selected several that are upregulated in UCC. The RNA within urinary cells and exosomes may be derived from bladder tumours, from the normal urothelium or be filtered from the glomerulus and secreted by the renal tubules ([@bib14]). As such the changes we observed may reflect events within the urothelium or the host\'s response to disease, masking tumour-specific miR changes.

Recent work has reported the use of three miRs in the detection of UCC ([@bib11]). The authors screened pooled urine samples from healthy controls, controls with urinary infections, patients with low-grade UCC and from patients with high-grade UCC for the expression of 157 miRs. They found miRs-126/152/199a were overrepresented in the urine from UCC cases and analysed these in a further 47 samples (*n*=11 controls and *n*=36 patients with UCC). In isolation or combination the three miR panel detected up to 77% of UCC cases (sensitivity 55%, specificity 82%). However, either of their selected miRs was altered in the UCC specimens we previously analysed ([@bib7]). Of note, in this report miR expression was normalised against miR-152. We found miR-152 had reduced expression in UCC (fivefold lower than normal urothelium) and thus may be a poor reference target. MiR-152 is located within a CpG island on Chromosome 17 and it\'s silencing by hypermethylation has been observed in breast cancer ([@bib15]).

To conclude, urinary miRs appear promising biomarkers for bladder cancer. We identified a panel of three miRs whose use would have found 94% of UCC, while reducing cystoscopy rates by 26% in patients with haematuria. However, this panel would have missed two invasive cancers (3%).
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![Detection of microRNA in urinary cell pellets. (**A**) The expression (presented as Ct value) of RNU48 and RNU44 and selected miRs in urine samples undergoing various processing protocols. \**P*-value \<0.001. (**B**) The relative expression (presented as the average ΔCt value) and the frequency of detection for each miR analysed is shown. MiRs with higher expression are detected more frequently and therefore make better biomarkers.](bjc2012221f1){#fig1}

![Expression of microRNA in urinary cell pellets. Unsupervised hierarchical clustering using either (**A**) eight or (**B**) three selected miRs identifies tree branches that mostly correspond to the underlying diagnosis. Average linkage correlation (uncentered) was performed on mean centred ΔCt values using Cluster 3.0. Samples are colour-labelled according to the pathology.](bjc2012221f2){#fig2}

![MicroRNAs-135b/15b/1224-3p and the diagnosis of bladder cancer. (**A**) Box plots show the expression profiles of each microRNA according to the presence of bladder cancer (box=95% CI and median=dark central bar). (**B**) Receiver operator curve for these two microRNAs alone and in combination for the detection of UCC (area under curve in brackets).](bjc2012221f3){#fig3}

###### Patients and tumours studied in this report

                       **Controls**   **UCC cases**           
  ------------------- -------------- --------------- -------- ----
  *Gender*                                                    
   Male                     35             66           53     78
   Female                   18             34           15     22
                                                                
  *Age*                                                       
   Median                   62                          72      
   Average                  58                          71      
   Range                  17--83                      38--87    
                                                                
  Haematuria                28             53                   
  Urolithiasis              10             19                   
  Urinary infection         6              11                   
  BPH (TURP)                6              11                   
  Other                     3               6                   
                                                                
  *Differentiation*                                           
   Grade 1                                              15     22
   Grade 2                                              21     31
   Grade 3                                              32     47
                                                                
  *Stage*                                                     
   pTa                                                  33     49
   pTis                                                 4      6
   pT1                                                  4      6
   pT2--4                                               27     40
                                                                
  Total                     53                          68      

Abbreviations: BPH=benign prostatic hyperplasia; TURP=trans-urethral resection of prostate; UCC=urothelial cell carcinoma.

Various controls including circumcision (1), pulmonary embolus (1), appendicitis (1).

###### MicroRNA expression in urinary samples from patients with bladder cancer and controls

                      **miR detected**          **Expression (ΔCt)**                                                                   
  ---------- -------- ------------------ ------ ---------------------- ------- ------- ------- ----------- ------ ------ ------ ------ ------
  miR-15a    Benign   50                 94.3                          6.35    4.14                                                     
             UCC      58                 85.3   0.03\*                 10.7    7.23    0.05    \<0.001\*   0.59   51.7   72.0   68.2   56.3
  miR-15b    Benign   48                 90.6                          3.29    3.36                                                     
             UCC      59                 86.8   0.4                    8.21    5.8     0.03    \<0.001\*   0.71   67.8   81.3   81.6   67.2
  miR-21     Benign   48                 90.6                          5.25    7.29                                                     
             UCC      58                 85.3   0.26                   6.08    6.58    0.56    0.5         0.51   46.6   56.3   56.3   46.6
  miR-23b    Benign   41                 77.4                          15.42   5.12                                                     
             UCC      21                 30.9   \<0.001\*              17.85   5.84    0.19    0.097       0.62   57.1   65.9   46.2   75.0
  miR-24-1   Benign   41                 77.4                          19.12   5.35                                                     
             UCC      51                 75.0   \<0.001\*              21.1    4.05    0.18    0.05\*      0.64   60.0   58.5   63.8   54.5
  miR-27b    Benign   53                 100                           3.33    2.76                                                     
             UCC      65                 95.6   \<0.001\*              7.39    3.76    0.06    \<0.001\*   0.67   60.3   81.1   79.2   63.2
  miR-100    Benign   47                 88.7                          8.96    5.83                                                     
             UCC      48                 70.6   0.01\*                 15.81   8.97    0.01    \<0.001\*   0.7    60.4   78.7   74.4   66.1
  miR-133b   Benign   5                  9.4                           23.9    7.65                                                     
             UCC      7                  10.3   0.87                   24.22   6.82    0.8     0.9         0.73   85.7   60.0   75.0   75.0
  miR-135b   Benign   43                 81.1                          13.64   5.27                                                     
             UCC      59                 86.8   0.28                   8.56    4.3     33.82   \<0.001\*   0.8    71.2   74.4   79.2   65.3
  miR-183    Benign   32                 60.4                          21.36   6.1                                                      
             UCC      19                 27.9   \<0.001\*              21.87   6.96    0.7     0.8         0.51   52.6   50.0   38.5   64.0
  miR-203    Benign   50                 94.3                          -1.68   2.57                                                     
             UCC      62                 91.2   0.21                   0.19    4.56    0.27    0.01\*      0.66   66.1   66.0   70.7   61.1
  miR-211    Benign   48                 90.6                          17.5    7.59                                                     
             UCC      28                 41.2   \<0.001\*              15.3    10.86   4.59    0.3         0.59   46.4   41.7   31.7   57.1
  miR-212    Benign   50                 94.3                          12.37   5.76                                                     
             UCC      62                 91.2   0.57                   14.94   5.18    0.16    0.012\*     0.59   54.2   64.0   64.0   54.2
  miR-328    Benign   53                 100                           10.6    3.54                                                     
             UCC      58                 85.3   \<0.001\*              18.23   7.97    0.005   \<0.001\*   0.71   55.4   86.8   81.6   64.8
  miR-1224   Benign   51                 96.2                          15.23   3.73                                                     
             UCC      61                 89.7   \<0.001\*              20.66   5.66    0.02    \<0.001\*   0.78   75.9   82.4   83.0   75.0

Abbreviations: ANOVA=analysis of variance; miR**=**microRNA; NPV=negative predictor value; PPV=positive predictor value; Sen=sensitivity; Spec=specificity; UCC=urothelial cell carcinoma. \*Statistical significance, *P*-value \<0.05.
